Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above 200 Day Moving Average – Should You Sell?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $26.57 and traded as high as $30.67. Celldex Therapeutics shares last traded at $29.48, with a volume of 650,121 shares traded.

Analyst Ratings Changes

CLDX has been the topic of several recent analyst reports. The Goldman Sachs Group increased their price objective on shares of Celldex Therapeutics from $30.00 to $34.00 and gave the company a “neutral” rating in a research report on Monday, March 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Wednesday, January 21st. Wolfe Research upgraded shares of Celldex Therapeutics from a “peer perform” rating to an “outperform” rating and set a $44.00 target price on the stock in a research note on Monday, March 23rd. Stifel Nicolaus reiterated a “buy” rating and set a $68.00 price target (up from $58.00) on shares of Celldex Therapeutics in a report on Thursday, February 26th. Finally, Barclays raised their price target on shares of Celldex Therapeutics from $21.00 to $24.00 and gave the company an “underweight” rating in a research report on Wednesday, December 17th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $44.45.

Celldex Therapeutics Trading Down 2.7%

The company’s 50 day simple moving average is $27.27 and its 200-day simple moving average is $26.57. The firm has a market cap of $1.96 billion, a P/E ratio of -7.58 and a beta of 1.17.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.22). Celldex Therapeutics had a negative return on equity of 41.67% and a negative net margin of 3,446.88%.The company had revenue of $0.12 million during the quarter, compared to the consensus estimate of $1.53 million. On average, sell-side analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Institutional Investors Weigh In On Celldex Therapeutics

A number of large investors have recently added to or reduced their stakes in CLDX. Invesco Ltd. grew its stake in shares of Celldex Therapeutics by 14.3% during the 4th quarter. Invesco Ltd. now owns 90,144 shares of the biopharmaceutical company’s stock valued at $2,448,000 after purchasing an additional 11,258 shares during the period. ADAR1 Capital Management LLC lifted its stake in shares of Celldex Therapeutics by 491.0% in the 4th quarter. ADAR1 Capital Management LLC now owns 646,767 shares of the biopharmaceutical company’s stock worth $17,566,000 after purchasing an additional 537,325 shares during the period. XTX Topco Ltd lifted its stake in shares of Celldex Therapeutics by 552.7% in the 4th quarter. XTX Topco Ltd now owns 51,523 shares of the biopharmaceutical company’s stock worth $1,399,000 after purchasing an additional 43,629 shares during the period. Virtus Investment Advisers LLC boosted its holdings in shares of Celldex Therapeutics by 72.9% in the fourth quarter. Virtus Investment Advisers LLC now owns 9,671 shares of the biopharmaceutical company’s stock worth $263,000 after buying an additional 4,079 shares during the last quarter. Finally, Wellington Management Group LLP boosted its holdings in shares of Celldex Therapeutics by 39.3% in the fourth quarter. Wellington Management Group LLP now owns 8,079,608 shares of the biopharmaceutical company’s stock worth $219,442,000 after buying an additional 2,279,605 shares during the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.